Item Type | Name |
Concept
|
Female
|
Concept
|
Genital Neoplasms, Female
|
Academic Article
|
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy.
|
Academic Article
|
Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma.
|
Academic Article
|
A LEEP cervical conization is rarely indicated for a two-step discrepancy.
|
Academic Article
|
Pathologic findings and outcomes for octogenarians presenting with uterine malignancy.
|
Academic Article
|
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
|
Academic Article
|
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
|
Academic Article
|
Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.
|
Academic Article
|
Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?
|
Academic Article
|
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
|
Academic Article
|
Society of Gynecologic Oncology 2016 Annual Meeting: Highlights and context.
|
Academic Article
|
Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.
|
Academic Article
|
Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome.
|
Academic Article
|
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
|
Academic Article
|
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
|
Academic Article
|
MICU1 drives glycolysis and chemoresistance in ovarian cancer.
|
Academic Article
|
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
|
Academic Article
|
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
|
Academic Article
|
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
|
Academic Article
|
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
|
Academic Article
|
Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
|
Academic Article
|
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
|
Academic Article
|
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
|
Academic Article
|
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
|
Academic Article
|
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
|
Academic Article
|
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
|
Academic Article
|
Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes.
|
Academic Article
|
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
|
Academic Article
|
Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy.
|
Academic Article
|
Endometrial Cancer: Is This a New Disease?
|
Academic Article
|
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
|
Academic Article
|
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
|
Academic Article
|
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
|
Academic Article
|
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
|
Academic Article
|
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
|
Academic Article
|
Developing a new radiomics-based CT image marker to detect lymph node metastasis among cervical cancer patients.
|
Academic Article
|
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers.
|
Academic Article
|
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
|
Academic Article
|
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
|
Academic Article
|
Cervical dysplasia among women over 35 years of age.
|
Academic Article
|
Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
|
Academic Article
|
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
|
Academic Article
|
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
|
Academic Article
|
Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
|
Academic Article
|
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
|
Academic Article
|
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
|
Academic Article
|
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.
|
Academic Article
|
Is the NCI MATCH trial a match for gynecologic oncology?
|
Academic Article
|
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
|
Academic Article
|
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
|
Academic Article
|
Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker.
|
Academic Article
|
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
|
Academic Article
|
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
|
Academic Article
|
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
|
Academic Article
|
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy.
|
Academic Article
|
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
|
Academic Article
|
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
|
Academic Article
|
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.
|
Academic Article
|
Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?
|
Academic Article
|
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
|
Academic Article
|
Patterns and utility of routine surveillance in high grade endometrial cancer.
|
Academic Article
|
Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis.
|
Academic Article
|
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.
|
Academic Article
|
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
|
Academic Article
|
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
|
Academic Article
|
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
|
Academic Article
|
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
|
Academic Article
|
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
|
Academic Article
|
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
|
Academic Article
|
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
|
Academic Article
|
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
|
Academic Article
|
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
|